Vivos Therapeutics Inc (VVOS)

May 22, 2026

Vivos Therapeutics Balances Rapid Growth With Cash Strain - TipRanks

May 22, 2026

May 22, 2026

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2026 Earnings Call Transcript - Insider Monkey

May 22, 2026

May 22, 2026

VVOS Stock Chart | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill

May 22, 2026

May 21, 2026

Vivos Therapeutics Earnings Call: Growth Meets Cash Strain - TipRanks

May 21, 2026

May 20, 2026

Vivos Therapeutics, Inc. 1Q 2026: Revenue $5.14M, EPS $(0.52) — 10-Q Summary - TradingView

May 20, 2026

May 20, 2026

Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 20, 2026

May 20, 2026

Vivos Therapeutics (NASDAQ: VVOS) Q1 2026 loss and going concern risk - Stock Titan

May 20, 2026

May 20, 2026

Vivos Therapeutics reports 70% revenue increase in Q1 2026 - Investing.com

May 20, 2026

May 20, 2026

Vivos Therapeutics reports 70% revenue increase in Q1 2026 By Investing.com - Investing.com Canada

May 20, 2026

May 20, 2026

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - The Manila Times

May 20, 2026

May 20, 2026

BRIEF-Vivos Therapeutics Q1 Net Income USD -7.751 Million - TradingView

May 20, 2026

May 20, 2026

Press Release: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - Moomoo

May 20, 2026

May 20, 2026

VVOS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

May 20, 2026

May 15, 2026

Vivos Therapeutics Delays Quarterly Filing - TipRanks

May 15, 2026

May 15, 2026

Vivos Therapeutics (VVOS) delays Q1 10-Q; preliminary revenue up ~70% - Stock Titan

May 15, 2026

May 15, 2026

Armistice Capital (NASDAQ: VVOS) reports 8.27% holding in Vivos Therapeutics - Stock Titan

May 15, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 11, 2026

[EFFECT] Vivos Therapeutics, Inc. SEC Filing - Stock Titan

May 11, 2026

May 10, 2026

Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential - MSN

May 10, 2026

May 10, 2026

Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges - TipRanks

May 10, 2026

May 08, 2026

3.96M warrant shares registered by Vivos (VVOS) for resale; $2.09 strike - Stock Titan

May 08, 2026

May 05, 2026

VVOS Forecast, Price Target & Analyst Ratings | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill

May 05, 2026

Apr 30, 2026

Vivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47 - MSN

Apr 30, 2026

Apr 29, 2026

Broadcom, Vivos Therapeutics and 3 stocks to watch heading into Monday - MSN

Apr 29, 2026

Apr 29, 2026

Vivos Therapeutics (NASDAQ: VVOS) registers 3.96M warrant-linked shares for resale - Stock Titan

Apr 29, 2026

Apr 24, 2026

VVOS Should I Buy - Intellectia AI

Apr 24, 2026

Apr 22, 2026

Vivos Therapeutics receives Nasdaq notice for stockholders’ equity deficiency - Investing.com

Apr 22, 2026

Apr 22, 2026

Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Apr 22, 2026

Apr 22, 2026

Equity shortfall puts Vivos Therapeutics (NASDAQ: VVOS) at Nasdaq delisting risk - Stock Titan

Apr 22, 2026

Apr 22, 2026

Qorvo To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga

Apr 22, 2026

Apr 21, 2026

Vivos Reports 16% Revenue Increase in 2025 Following Business Model Shift - Sleep Review

Apr 21, 2026

Apr 20, 2026

Vivos Therapeutics stock price target lowered to $2.50 by H.C. Wainwright - Investing.com Australia

Apr 20, 2026

Apr 18, 2026

New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM ESTShow #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Viv - ACCESS Newswire

Apr 18, 2026

Apr 17, 2026

H.C. Wainwright Maintains Vivos Therapeutics(VVOS.US) With Buy Rating, Cuts Target Price to $2.5 - 富途牛牛

Apr 17, 2026

Apr 17, 2026

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call Transcript - Insider Monkey

Apr 17, 2026

Apr 16, 2026

Vivos Therapeutics (VVOS) Stock: Why Cash Position (Freefalls) 2026-04-16Trending Entry Points - UBND thành phố Hải Phòng

Apr 16, 2026

Apr 16, 2026

Vivos Therapeutics Balances Growth Hopes With Cash Strain - TipRanks

Apr 16, 2026

Apr 16, 2026

Vivos Therapeutics Reports Full Year 2025 Financial Results - ADVFN

Apr 16, 2026

Apr 16, 2026

Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada

Apr 16, 2026

Apr 16, 2026

Vivos Therapeutics Reports 16% Revenue Growth in 2025, Advances Sleep Center Integration and Eyes Cash Flow Positive Operations - Minichart

Apr 16, 2026

Apr 15, 2026

Vivos Therapeutics Pivots to Medical-Provider Focused Model with Sleep Center of Nevada Acquisition to Expand Sleep Apnea Solutions 91 - Minichart

Apr 15, 2026

Apr 15, 2026

Earnings call transcript: vivos beats Q4 2025 earnings expectations - Investing.com UK

Apr 15, 2026

Apr 15, 2026

VVOS: 2025 revenue rose 16% as SCN integration fueled growth, with further expansion planned for 2026 - TradingView

Apr 15, 2026

Apr 15, 2026

Earnings Call Summary | Vivos Therapeutics(VVOS.US) Q4 2025 Earnings Conference - 富途牛牛

Apr 15, 2026

Apr 15, 2026

VVOS: 2025 revenue up 16% from SCN integration, with strong growth outlook as new model scales - TradingView

Apr 15, 2026